Organization (Industry)
COLGATE-PALMOLIVE COMPANY
ClinicalTrials.gov lists COLGATE-PALMOLIVE COMPANY as lead sponsor of 116 trials, counting the companies grouped under it. COLGATE-PALMOLIVE COMPANY itself has 114 active development programs and 32 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 19 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 23 in 2026 and about 18 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo Colgate-Palmolive, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers COLGATE-PALMOLIVE COMPANY and 1 company grouped under it: 116 lead-sponsored trials (115 its own, 1 in the grouped companies) and 6 legal-entity registrations (6 its own, 0 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Gaba International AG | 1 | 0 |
Disease areas (28)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Gingivitis | 50 |
| Dental Plaque | 37 |
| Plaque, Amyloid | 16 |
| Dental Caries | 14 |
| Dentin Sensitivity | 7 |
Showing 5 of 28 disease areas.
Trials by start year as sponsor or collaborator (22)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 19 |
| 2025 | 16 |
| 2024 | 18 |
| 2023 | 7 |
| 2022 | 5 |
| 2021 | 7 |
| 2020 | 7 |
| 2019 | 5 |
| 2018 | 3 |
| 2017 | 7 |
Showing 10 of 22 years.
Prediction, not a registry value: median of 12 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 3 months across 98 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (114)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Colgate Cavity Protection Toothpaste | Plaque, Amyloid | Phase 3 | 2 |
| Meridol | Plaque, Amyloid | Phase 3 | 2 |
| Meridol | Gingivitis | Phase 3 | 2 |
| Silica Free Meridol | Plaque, Amyloid | Phase 3 | 1 |
| Silica Free Meridol | Gingivitis | Phase 3 | 1 |
Showing 5 of 114 active programs.
Approved assets (32)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Stannous Fluoride Toothpaste | 10 |
| Colgate Cavity Protection Toothpaste | 8 |
| Potassium Nitrate Toothpaste | 7 |
| Fluoride Toothpaste | 5 |
| Triclosan/Fluoride toothpaste | 3 |
Showing 5 of 32 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 64% hit target (n=33) | 66% on time (n=35) |
Journals published in (36)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of periodontology | 6 |
| Caries research | 3 |
| Journal of clinical periodontology | 3 |
| Journal of the American Dental Association (1939) | 3 |
| Archives of oral biology | 2 |
Showing 5 of 36 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 5,050 | 471 | 2025-12-30 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 20,382,000,000 | 2,132,000,000 | 366,000,000 |
| 2024 | 20,101,000,000 | 2,889,000,000 | 355,000,000 |
| 2023 | 19,457,000,000 | 2,300,000,000 | 343,000,000 |
| 2022 | 17,967,000,000 | 1,785,000,000 | 320,000,000 |
| 2021 | 17,421,000,000 | 2,166,000,000 | 307,000,000 |
| 2020 | 16,471,000,000 | 2,695,000,000 | 290,000,000 |
| 2019 | 15,693,000,000 | 2,367,000,000 | 281,000,000 |
| 2018 | 15,544,000,000 | 2,400,000,000 | 277,000,000 |
| 2017 | 15,454,000,000 | 2,024,000,000 | 285,000,000 |
| 2016 | 15,195,000,000 | 2,441,000,000 | 289,000,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (20)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-11-10 | Debt financing | not disclosed | Sec extracted |
| 2025-11-05 | Debt financing | 689,067,840 | Edgar offerings |
| 2025-11-03 | Other financing | not disclosed | Edgar offerings |
| 2025-05-02 | Debt financing | 500,000,000 | Sec extracted |
| 2025-04-30 | Debt financing | 499,750,000 | Edgar offerings |
Showing 5 of 20 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 19 |
FDA recalls (7)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| hello wild strawberry fluoride toothpaste, sodium fluoride 0.24% (0.15% w/v fluoride ion), NET WT 4.2 OZ (119 g), Distributed by Hello Products LLC, Montclair, NJ 07042, UPC 8 19156 02026 4 (carton), 12-count case GTIN: 20819156020268; strawberry tubes also sold in Strawberry 3-pack overwrap UPC 8 19156 02349 4, UPC 10819156023491 case; in the variety 3-pack of Strawberry + Unicorn + Grape UPC 8 19156 02332 6, UPC 10819156023323 case; and in a 24-count Toothpaste Floorstand, UPC 819156020684 (case). | Class II | 2023-08-10 |
| PreviDent 5000 ppm, DRY MOUTH, 1.1% Sodium Fluoride, PRESCRIPTION STRENGTH TOOTHPASTE, SLS Free Formula, SOOTHING MINT, 3.4 FL OZ (100 mL), Colgate Oral Pharmaceuticals, Inc., New York, NY 10022 --- NDC 0126-0016-61, UPC 3834110622 | Class III | 2017-02-13 |
| Colgate Adult Motion Battery Toothbrush UPC 035000686213 Dist. by Colgate-Palmolive Co. New York, NY 10022 Made in China. For teeth cleansing. | Class II | 2012-03-23 |
| Colgate Adult Motion Whitening Battery Toothbrush UPC 035000691507 Dist. by Colgate-Palmolive Co. New York, NY 10022 Made in China. For teeth cleansing. | Class II | 2012-03-23 |
| Colgate 360 Replaceable Head Battery Powered Toothbrush Medium UPC03500068750 Dist. by Colgate-Palmolive Co. New York, NY 10022 Made in China. For teeth cleansing. | Class II | 2012-03-23 |
Showing 5 of 7 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 7 | 2024-06-07 |
Manufacturing and distribution sites (5)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Colgate-Palmolive Company | PISCATAWAY, US | FDA | |
| Colgate-Palmolive Company | Piscataway, US | Health Canada | |
| Colgate-Palmolive Company | Hodges, US | FDA, Health Canada | |
| Colgate-Palmolive Company | Morristown, US | FDA, Health Canada | |
| Colgate-Palmolive Company | Morristown, US | Health Canada |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | yes |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (5,291)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 5,291 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| COLGATE PALMOLIVE CO | Certificate of registration | Terminated |
Biomarker capability evidence (36)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CRP | Trial sponsor | Primary endpoint in a Phase 3 trial |
| CRP | Trial sponsor | Primary endpoint in a Phase 3 trial |
| GCFC2 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| GCFC2 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| GOPC | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 36 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, fda warning letters, fda untitled letters, organization relationships, and biomarkers this organization publishes on.